FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2127408422> ?p ?o ?g. }

• W2127408422 abstract "The current healthcare climate demands pharmacoeconomic evaluations for different treatment strategies incorporating drug acquisition costs, costs incurred for hospitalisation, drug administration and preparation, diagnostic and laboratory testing and drug-related adverse events (AEs). Here we evaluate the pharmacoeconomics of voriconazole versus liposomal amphotericin B as first-line therapies for invasive aspergillosis (IA) in patients with haematological malignancy and prolonged neutropenia or who were undergoing haematopoietic stem-cell transplantation in Germany or Spain.A decision analytic model based on a decision tree was constructed to estimate the potential treatment costs of voriconazole versus liposomal amphotericin B. Each model pathway was defined by the probability of an event occurring and the costs of clinical outcomes. Outcome probabilities and cost inputs were derived from the published literature, clinical trials, expert panels and local database costs. In the base case, patients who failed to respond to first-line therapy were assumed to experience a single switch between comparator drugs or the other drug was added as second-line treatment. Base-case evaluation included only drug-management costs and additional hospitalisation costs due to severe AEs associated with first- and second-line therapies. Sensitivity analyses were conducted to assess the robustness of the results. Cost estimates were inflated to 2011 euros (€).Based on clinical trial success rates of 52.8% (voriconazole) and 50.0% (liposomal amphotericin B), voriconazole had lower total treatment costs compared with liposomal amphotericin B in both Germany (€ 12,256 versus € 18,133; length of therapy [LOT] = 10-day intravenous [IV] + 5-day oral voriconazole and 15-day IV liposomal amphotericin B) and Spain (€ 8,032 versus € 10,516; LOT = 7-day IV + 8-day oral voriconazole and 15-day IV liposomal amphotericin B). Assuming the same efficacy (50.0%) in first-line therapy, voriconazole maintained a lower total treatment cost compared with liposomal amphotericin B. Cost savings were primarily due to the lower drug acquisition costs and shorter IV LOT associated with voriconazole. Sensitivity analyses showed that the results were sensitive to drug price, particularly the cost of liposomal amphotericin B.Voriconazole is likely to be cost-saving compared with liposomal amphotericin B when used as a first-line treatment for IA in Germany and Spain." @default.
• W2127408422 created "2016-06-24" @default.
• W2127408422 creator A5018220025 @default.
• W2127408422 creator A5024580938 @default.
• W2127408422 creator A5026321359 @default.
• W2127408422 creator A5031938441 @default.
• W2127408422 creator A5051016771 @default.
• W2127408422 creator A5054098287 @default.
• W2127408422 creator A5055958896 @default.
• W2127408422 creator A5067433767 @default.
• W2127408422 creator A5075722788 @default.
• W2127408422 creator A5081446167 @default.
• W2127408422 creator A5086766354 @default.
• W2127408422 date "2014-09-24" @default.
• W2127408422 modified "2023-10-10" @default.
• W2127408422 title "Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain" @default.
• W2127408422 cites W1871775279 @default.
• W2127408422 cites W1969880613 @default.
• W2127408422 cites W1986071890 @default.
• W2127408422 cites W1996957496 @default.
• W2127408422 cites W2000502211 @default.
• W2127408422 cites W2008594793 @default.
• W2127408422 cites W2012050459 @default.
• W2127408422 cites W2019992215 @default.
• W2127408422 cites W2028652300 @default.
• W2127408422 cites W2056914772 @default.
• W2127408422 cites W2070088559 @default.
• W2127408422 cites W2079560112 @default.
• W2127408422 cites W2082695689 @default.
• W2127408422 cites W2099769947 @default.
• W2127408422 cites W2110055188 @default.
• W2127408422 cites W2123114992 @default.
• W2127408422 cites W2132239975 @default.
• W2127408422 cites W2135290759 @default.
• W2127408422 cites W2135577396 @default.
• W2127408422 cites W2136607722 @default.
• W2127408422 cites W2136710582 @default.
• W2127408422 cites W2138648278 @default.
• W2127408422 cites W2145618654 @default.
• W2127408422 cites W2146558016 @default.
• W2127408422 cites W2150824761 @default.
• W2127408422 cites W2158382206 @default.
• W2127408422 cites W2166875150 @default.
• W2127408422 cites W2198551535 @default.
• W2127408422 cites W4378951071 @default.
• W2127408422 doi "https://doi.org/10.1186/2050-6511-15-52" @default.
• W2127408422 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4183350" @default.
• W2127408422 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25253630" @default.
• W2127408422 hasPublicationYear "2014" @default.
• W2127408422 type Work @default.
• W2127408422 sameAs 2127408422 @default.
• W2127408422 citedByCount "16" @default.
• W2127408422 countsByYear W21274084222015 @default.
• W2127408422 countsByYear W21274084222016 @default.
• W2127408422 countsByYear W21274084222017 @default.
• W2127408422 countsByYear W21274084222018 @default.
• W2127408422 countsByYear W21274084222019 @default.
• W2127408422 countsByYear W21274084222021 @default.
• W2127408422 countsByYear W21274084222022 @default.
• W2127408422 countsByYear W21274084222023 @default.
• W2127408422 crossrefType "journal-article" @default.
• W2127408422 hasAuthorship W2127408422A5018220025 @default.
• W2127408422 hasAuthorship W2127408422A5024580938 @default.
• W2127408422 hasAuthorship W2127408422A5026321359 @default.
• W2127408422 hasAuthorship W2127408422A5031938441 @default.
• W2127408422 hasAuthorship W2127408422A5051016771 @default.
• W2127408422 hasAuthorship W2127408422A5054098287 @default.
• W2127408422 hasAuthorship W2127408422A5055958896 @default.
• W2127408422 hasAuthorship W2127408422A5067433767 @default.
• W2127408422 hasAuthorship W2127408422A5075722788 @default.
• W2127408422 hasAuthorship W2127408422A5081446167 @default.
• W2127408422 hasAuthorship W2127408422A5086766354 @default.
• W2127408422 hasBestOaLocation W21274084221 @default.
• W2127408422 hasConcept C112930515 @default.
• W2127408422 hasConcept C126322002 @default.
• W2127408422 hasConcept C16005928 @default.
• W2127408422 hasConcept C177713679 @default.
• W2127408422 hasConcept C197934379 @default.
• W2127408422 hasConcept C203014093 @default.
• W2127408422 hasConcept C2776391196 @default.
• W2127408422 hasConcept C2776694085 @default.
• W2127408422 hasConcept C2776738588 @default.
• W2127408422 hasConcept C2777063308 @default.
• W2127408422 hasConcept C2779548794 @default.
• W2127408422 hasConcept C2779629538 @default.
• W2127408422 hasConcept C2780690907 @default.
• W2127408422 hasConcept C3019080777 @default.
• W2127408422 hasConcept C535046627 @default.
• W2127408422 hasConcept C71924100 @default.
• W2127408422 hasConceptScore W2127408422C112930515 @default.
• W2127408422 hasConceptScore W2127408422C126322002 @default.
• W2127408422 hasConceptScore W2127408422C16005928 @default.
• W2127408422 hasConceptScore W2127408422C177713679 @default.
• W2127408422 hasConceptScore W2127408422C197934379 @default.
• W2127408422 hasConceptScore W2127408422C203014093 @default.
• W2127408422 hasConceptScore W2127408422C2776391196 @default.
• W2127408422 hasConceptScore W2127408422C2776694085 @default.
• W2127408422 hasConceptScore W2127408422C2776738588 @default.
• W2127408422 hasConceptScore W2127408422C2777063308 @default.
• W2127408422 hasConceptScore W2127408422C2779548794 @default.

• next